The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future

被引:29
作者
Hamming, Lisanne C. [1 ]
Slotman, Ben J. [2 ]
Verheul, Henk M. W. [1 ]
Thijssen, Victor L. [2 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands
关键词
Angiogenesis; Radiation; Angiostatic drugs; Clinical trials; Cancer; Combination therapy; ADVANCED RECTAL-CANCER; PHASE-II-TRIAL; BEVACIZUMAB PLUS IRINOTECAN; RECOMBINANT HUMAN ENDOSTATIN; RENAL-CELL CARCINOMA; RADIATION-THERAPY; PREOPERATIVE TREATMENT; IONIZING-RADIATION; POSTOPERATIVE; 5-FLUOROURACIL; FRACTIONATED RADIOTHERAPY;
D O I
10.1007/s10456-017-9546-9
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Although monotherapy with angiostatic drugs is still far from effective, there is abundant evidence that angiostatic therapy can improve the efficacy of conventional treatments like radiotherapy. This has instigated numerous efforts to optimize and clinically implement the combination of angiostatic drugs with radiation treatment. The results from past and present clinical trials that explored this combination therapy indeed show encouraging results. However, current findings also show that the combination has variable efficacy and is associated with increased toxicity. This indicates that combining radiotherapy with angiostatic drugs not only holds opportunities but also provides several challenges. In the current review, we provide an update of the most recent insights from clinical trials that evaluated the combination of angiostatic drugs with radiation treatment. In addition, we discuss the outstanding questions for future studies in order to improve the clinical benefit of combining angiostatic therapy with radiation therapy.
引用
收藏
页码:217 / 232
页数:16
相关论文
共 115 条
[1]  
[Anonymous], 2004, FDA Consum, V38, P17
[2]  
[Anonymous], 2016, DIS ESOPHAGUS, DOI DOI 10.1111/dote.12444
[3]  
[Anonymous], 1994, RADIAT ONCOL INVEST
[4]   Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial [J].
Avallone, Antonio ;
Pecori, Biagio ;
Bianco, Franco ;
Aloj, Luigi ;
Tatangelo, Fabiana ;
Romano, Carmela ;
Granata, Vincenza ;
Marone, Pietro ;
Leone, Alessandra ;
Botti, Gerardo ;
Petrillo, Antonella ;
Caraco, Corradina ;
Iaffaioli, Vincenzo R. ;
Muto, Paolo ;
Romano, Giovanni ;
Comella, Pasquale ;
Budillon, Alfredo ;
Delrio, Paolo .
ONCOTARGET, 2015, 6 (30) :30394-30407
[5]  
Bani M, 2017, ANGIOGENESIS, V20, P233, DOI 10.1007/s10456-017-9549-6
[6]   Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer [J].
Bao, Yong ;
Peng, Fang ;
Zhou, Qi-Chao ;
Yu, Zhong-Hua ;
Li, Jian-Cheng ;
Cheng, Zhi-Bin ;
Chen, Long ;
Hu, Xiao ;
Chen, Yuan-Yuan ;
Wang, Jin ;
Wang, Yan ;
Ma, Hong-Lian ;
Xu, Zu-Min ;
Lu, Ru-Biao ;
Deng, Xiao-Wu ;
Chen, Ming .
RADIOTHERAPY AND ONCOLOGY, 2015, 114 (02) :161-166
[7]  
Bendell Johanna C, 2012, Clin Adv Hematol Oncol, V10, P430
[8]   Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment [J].
Berndsen, Robert H. ;
Abdul, U. Kulsoom ;
Weiss, Andrea ;
Zoetemelk, Marloes ;
te Winkel, Marije T. ;
Dyson, Paul J. ;
Griffioen, Arjan W. ;
Nowak-Sliwinska, Patrycja .
ANGIOGENESIS, 2017, 20 (02) :245-267
[9]   Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer [J].
Blaszkowsky, L. S. ;
Ryan, D. P. ;
Szymonifka, J. ;
Borger, D. R. ;
Zhu, A. X. ;
Clark, J. W. ;
Kwak, E. L. ;
Mamon, H. J. ;
Allen, J. N. ;
Vasudev, E. ;
Shellito, P. C. ;
Cusack, J. C. ;
Berger, D. L. ;
Hong, T. S. .
ANNALS OF ONCOLOGY, 2014, 25 (01) :121-126
[10]   Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study [J].
Borg, C. ;
Andre, T. ;
Mantion, G. ;
Boudghene, F. ;
Mornex, F. ;
Maingon, P. ;
Adenis, A. ;
Azria, D. ;
Piutti, M. ;
Morsli, O. ;
Bosset, J. F. .
ANNALS OF ONCOLOGY, 2014, 25 (11) :2205-2210